• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 19th January 2016

From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers

Paula Lorgelly, Deputy Director of OHE, reviews HTA decision making processes in three comparable countries, and considers the agency problem and possible solutions. On 14th of December 2015 OHE’s new Deputy Director, Paula Lorgelly, presented an OHE lunchtime seminar on…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Paula Lorgelly, Deputy Director of OHE, reviews HTA decision making processes in three comparable countries, and considers the agency problem and possible solutions.

On 14th of December 2015 OHE’s new Deputy Director, Paula Lorgelly, presented an OHE lunchtime seminar on HTA decision making, comparing New Zealand, Australia and the United Kingdom in terms of the processes in place to consider affordability.  The seminar concluded with a discussion of the HTA process as an agency problem.

The decision-making criteria employed by health technology assessment (HTA) agencies differs between countries.  Researchers have previously analysed HTA decisions, in an attempt to understand the influence of specific factors on decisions, both within and across jurisdictions. 

Despite agencies effectively evaluating the same clinical evidence base, adoption decisions vary.  This could be due to different economic and health system contexts, social values, an agency’s ability to price-negotiate or the process.  Recently, it has been argued that it is time that the National Institute for Health and Care Excellence (NICE) revisited its processes or, more specifically, its criteria for making decisions.  In the current austere climate one criterion that warrants discussion is that of affordability.

While NICE, the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia and the Pharmaceutical Management Agency (PHARMAC) in New Zealand may on the face of it seem similar, in one respect – that of assessing affordability – they are very different.  

NICE’s guidance is mandatory, yet it has no influence over the funding budget nor does it suggest where the money should come from to fund the technologies it recommends. 

PBAC’s remit allows them to make recommendations on listing and funding treatments, such that in their deliberations they also consider the financial cost/budget impact of listing. 

PHARMAC works within a capped budget, such that it may recommend a technology for listing but if the budget is exhausted, it then it simply cannot be funded.

Sofosbuvir for hepatitis C, Pembrolizumab for melanoma and Trastuzumab Emtansine for breast cancer were presented as case studies to understand how each HTA agency informs a listing decision and separately a funding decision.

The presentation concluded with an application of the principal-agent problem to HTA decision making.  The health service or health system is the principal and the HTA agency the agent.  An agency problem occurs if the preferences and incentives of the principal and agent do not align.  The agency problem is further complicated if we regard the general public (or patients) as the principal, the health service their agent, and the HTA agency their agent.  In effect NICE is a double agent. 

To address the agency problem we need to consider both the misspecification of the objective function (what is each party seeking to maximise and is it the same) and the misspecification of the constraint (understanding the opportunity cost by understanding the budget). 

If NICE were a threshold searcher then they would consider the budget and affordability issues when evaluating HTA decision; and not unlike PHARMAC they would need to make disinvestment decisions also.  This would mean that when looking to adopt technologies with non-marginal effects on the budget they could change the cost effectiveness threshold (which is what PBAC did for the suite of hepatitis C drugs), so the adoption decision reflects both the cost effectiveness of the technology and its affordability.  However, this requires fungible budgets.

 

Lunchtime Seminar with Paula Lorgelly – 14 December 2015 from Office of Health Economics

For more information, contact Paula Lorgelly at OHE.

 

  • Value, Affordability, and…

Related News

Group 11119
  • News
  • February 2023

Applications open for MSc Fellowship Programme 2023

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!